German Pharma Company Building $65 Million R&D Center in Connecticut
11/22/2011
The center will not add many permanent jobs, according to James Baxter, Boehringer's U.S. senior vice president for development. However, he noted the company's 25 employees R&D facility will remain in Ridgefield, as will other positions (about 100) dependent upon the work performed at the facility.
Based in Ridgefield, CT, Boehringer Ingelheim Pharmaceuticals is the largest U.S. subsidiary of Boehringer Ingelheim Corporation. It also is a member of the Boehringer Ingelheim group of companies (headquartered in Ingelheim, Germany), which operates globally with 145 affiliates and more than 42,000 employees.
Project Announcements
Avail Enclosure Systems Plans Kent County, Maryland, Operations
03/13/2025
Frontier Lithium Plans Thunder Bay, Ontario, Canada, Chemical Production Operations
03/10/2025
Germany-Based thyssenkrupp Materials Plans Santa Teresa, New Mexico, Operations
03/10/2025
Triple Point Security Plans Salt Lake City, Utah, Operations
03/10/2025
SIXT USA Plans Tulsa, Oklahoma, Operations
03/10/2025
ViDARR Plans Virginia Beach, Virginia, Manufacturing Operations
03/10/2025
Most Read
-
The Workforce Factor: How States Are Competing to Build Tomorrow's Talent
Q4 2024
-
NEW NIMBYism: A Threat to The U.S. Economy
Q4 2024
-
Designing Beyond the Assembly Line
Q1 2025
-
Microsoft-Three Mile Island Deal Could Signal Path for Nuclear Power to Strengthen Partnerships with Big Tech
Q4 2024
-
Industries Look for Employees in Nontraditional Spaces Amid Labor Shortage
Q4 2024
-
Forging Solid Foundations
Q1 2025
-
Why Decarbonization Goals Start with Site Selection
Q4 2024